Patent classifications
C07D277/42
Inhibitor of indoleamine-2,3-dioxygenase (IDO)
The present disclosure provides compounds of Formula (I). The compounds described herein may be useful in treating a disease associated with IDO, for example, cancer or an infectious disease (e.g., viral or bacterial infectious diseases). Also, provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein. ##STR00001##
COLORED PHOTOSENSITIVE RESIN COMPOSITION
An object of the present invention is to provide a colored photosensitive resin composition capable of forming a color filter having a higher brightness than that of the color filter formed from the conventionally known colored photosensitive resin composition.
The colored photosensitive resin composition according to the present invention comprises a colorant, a resin, a polymerizable compound, and a polymerization initiator, the colorant comprising a compound represented by formula (1) and an α-type and/or β-type copper phthalocyanine pigment,
##STR00001##
wherein M.sup.r+ represents an r-valent metal ion; k represents the sum of the number of —SO.sub.3.sup.− and the number of —SO.sub.2—N.sup.−—SO.sub.2—R.sup.f in the compound represented by formula (1); r represents an integer of 1 or more; R.sup.f represents a fluoroalkyl group having 1 to 12 carbon atoms; and the compound represented by formula (1) has at least one —SO.sub.3.sup.− or —SO.sub.2—N.sup.−—SO.sub.2—R.sup.f.
SSAO inhibitor
The present invention provides an SSAO inhibitor and an application thereof in preparing a drug for treating a disease related to SSAO. In particular, the present invention provides a compound shown in formula (IV) and a pharmaceutically acceptable salt thereof. ##STR00001##
GP130 modulators
There are provided, inter alia, compounds and methods useful for the treatment of neurological conditions, such as neurological disorders and neurodegenerative diseases, including Alzheimer's Disease.
GP130 modulators
There are provided, inter alia, compounds and methods useful for the treatment of neurological conditions, such as neurological disorders and neurodegenerative diseases, including Alzheimer's Disease.
NEUROPROTECTIVE COMPOSITIONS AND METHODS OF USING THE SAME
This invention is directed to neuroprotective compositions and methods of using the same to treat neurodegenerative diseases.
PROTEIN AND LIPID THERAPEUTIC TARGETS
Disclosed are compounds and methods for preventing or treating necroinflammation associated with ferroptotic processes. The method includes inhibiting 15 lipoxygenase/phosphatidylethanolamine binding protein (15LOX/PEBP1) complex, wherein the inhibitor exhibits a higher binding affinity or binding activity for 15LOX/PEBP1 complex compared to 15LOX alone. Necroinflammation associated with ferroptotic processes causes several pathogenic conditions including upper or lower respiratory disorders, acute or chronic brain injury, renal injury, injury by radiation, neurodegenerative disorder, among others. The disclosed compounds and methods are useful in subjects diagnosed with one or more of these conditions.
PROTEIN AND LIPID THERAPEUTIC TARGETS
Disclosed are compounds and methods for preventing or treating necroinflammation associated with ferroptotic processes. The method includes inhibiting 15 lipoxygenase/phosphatidylethanolamine binding protein (15LOX/PEBP1) complex, wherein the inhibitor exhibits a higher binding affinity or binding activity for 15LOX/PEBP1 complex compared to 15LOX alone. Necroinflammation associated with ferroptotic processes causes several pathogenic conditions including upper or lower respiratory disorders, acute or chronic brain injury, renal injury, injury by radiation, neurodegenerative disorder, among others. The disclosed compounds and methods are useful in subjects diagnosed with one or more of these conditions.
COMPOSITIONS AND METHODS FOR MODULATING INFLAMMATORY AND DEGENERATIVE DISORDER
The disclosure provides compounds and method useful for modulating gp130 biological activity. The disclosure also provides methods and compositions for treating disease and disorders associated with gp130 activity, particularly those associated with inflammation.
METHIONINE METABOLIC PATHWAY INHIBITORS
The present invention provides novel inhibitors of cystathionin gamma synthase (CGS), their use as selective and non-selective herbicides, agricultural and non-agricultural herbicides, herbicides in integrated pest management, herbicides for gardening, clearing waste ground, clearing industrial or constructions sites, clearing railways and railway embankments, pesticide, fungicide, agricultural plant stimulant or antimicrobial agent. Also provided is a method for the control of undesired vegetation or clearing areas from the undesired vegetation comprising applying to the locus of said undesired vegetation, to the undesired plants or to a habitat thereof, a herbicidally effective amount of the compound of the present invention.